Cost Audit › Pharmaceuticals

Cost Audit for Pharmaceutical Companies: Lower Thresholds, Closer Scrutiny

Drugs and pharmaceuticals sit in the regulated sector table — meaning cost audit applies at a lower turnover than most manufacturing industries. Many pharma companies are covered sooner than they realize.

Pharma Cost Audit
Regulated-sector thresholds applied
₹50cr / ₹25cr tested

Overview

Why Pharma Faces Lower Cost Audit Thresholds

Drugs and pharmaceuticals are classified as a regulated sector under Rule 3 of the Companies (Cost Records and Audit) Rules, 2014 — grouped with telecom, electricity and petroleum products. This means cost audit applies once overall turnover reaches ₹50 crore, with turnover from the specific drug or formulation reaching ₹25 crore, considerably lower than the ₹100 crore/₹35 crore thresholds most non-regulated manufacturers face.

Who Needs This

Which Pharma Companies Are Covered

Formulation manufacturers
Bulk drug/API producers
Biopharma companies
Foreign pharma subsidiaries

Regulated Sector Thresholds

Why Pharma Gets Covered Sooner

Regulated Sector Status

Grouped with telecom, electricity and petroleum under Rule 3

₹50cr overall turnover
Considerably lower than the ₹100cr non-regulated threshold
Per-Formulation Threshold

Applies at the individual drug or formulation level, not just company-wide

₹25cr product-level turnover
A single high-volume formulation can trigger applicability on its own
Why the lower threshold exists

Pharmaceuticals are treated as a regulated sector because of their direct link to public health pricing and essential drug availability, which is why the applicability bar sits lower than for general manufacturing.

Why It Matters

Why This Matters for Pharma Companies Specifically

Avoid falling behind schedule

Lower thresholds mean many pharma companies are covered earlier than expected.

Formulation-level cost clarity

Per-drug costing supports pricing decisions under margin pressure.

API/bulk drug cost tracking

Raw material cost volatility is captured accurately in cost records.

Regulatory-readiness

A clean cost audit trail supports broader regulatory and pricing scrutiny.

Batch-level inventory accuracy

Inventory valuation is tracked consistently across production batches.

Cross-border consistency

Foreign pharma subsidiaries get the same rule-based assessment.

How It Works

Our Process for Pharmaceutical Cost Audits

Built around formulation-level costing and regulated-sector timelines.

Start My Pharma Audit
Regulated sector confirmation

We confirm your products fall within the drugs and pharmaceuticals category under Rule 3.

2
Threshold testing

Overall and per-formulation turnover are tested against the ₹50cr/₹25cr thresholds.

3
Batch cost records review

Cost records are reviewed at the batch and formulation level.

4
Cost audit execution

The audit is carried out per formulation, consistent with Cost Accounting Standards.

5
CRA-3 / CRA-4 filing

The report is finalized and filed with the MCA within statutory timelines.

Before You Start

Documents We Need From Pharma Companies

Formulation-wise cost data
Batch production records
Financial statements
Raw material/API purchase data

Sector Coverage

Industries We Serve

Electronics
Pharmaceutical
Chemicals
Engineering
Auto Components
Semiconductor
Manufacturing
Foreign Companies

Why SSCOIndia

Why Pharma Companies Choose SSCOIndia

ICMAI Cost Accountants
Written compliance position
Fast, no-obligation review
PAN India, foreign entities too

Questions

Frequently Asked Questions

Drugs and pharmaceuticals are classified as a regulated sector under Rule 3, alongside telecom, electricity and petroleum, which carries lower turnover thresholds than non-regulated manufacturing.

Cost audit applies once overall turnover reaches ₹50 crore, with turnover from a specific drug or formulation reaching ₹25 crore or more.

Both are tested — overall company turnover against the ₹50 crore mark, and the specific formulation or product's turnover against the ₹25 crore mark.

Yes, bulk drug and API manufacturers fall within the same regulated sector classification as formulation companies.

Coverage depends on whether the specific products fall within the notified drugs and pharmaceuticals category — this is assessed case by case.

Cost records are typically maintained and reviewed at the batch level, since material and overhead costs can vary meaningfully batch to batch.

Yes, foreign pharma subsidiaries or manufacturing units in India are assessed under the same regulated sector thresholds as domestic companies.

While separate regimes, a clean cost audit trail can support a company's position in broader pricing and regulatory reviews.

Formulation-wise cost data, batch production records, raw material and API purchase data, and financial statements.

Yes, we work with formulation and API manufacturers on batch-level costing and full regulated-sector cost audit compliance.

Need Help With For Pharmaceutical Companies?

Book a free consultation and get a clear compliance position before you commit to anything.

Call Book Free Consultation